Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Acute and subacute effects of the selective serotonin-noradrenaline reuptake inhibitor duloxetine on cardiac hERG channels.
Fischer F
,
Vonderlin N
,
Seyler C
,
Zitron E
,
Schernus B
,
Katus H
,
Scholz E
.
???displayArticle.abstract???
Duloxetine is a selective serotonin-noradrenaline reuptake inhibitor approved for treatment of major depressive disorder. So far, duloxetine has been found to be well tolerated and reported cardiac side effects were negligible. However, pharmacological effects on cardiac hERG channels have not been properly addressed yet. hERG channels were expressed in Xenopus oocytes and a human embryonic kidney (HEK) cell line. Currents were measured using voltage clamp and patch clamp techniques. Channel surface expression was quantified using Western blot analysis. We found that duloxetine inhibits heterologously expressed hERG channels in a concentration-dependent manner, yielding an IC50 of 142.8 μM in Xenopus oocytes. Inhibitory effects were even more pronounced when using a mammalian cell line resulting in a 34 or 59% current decrease by 10 or 30 μM duloxetine, respectively. Duloxetine did not affect channel activation or inactivation kinetics. However, channel deactivation was accelerated by duloxetine. We further showed that inhibition occurs in the open and inactivated, but not closed, states. There was no frequency dependence of block. However, effects of duloxetine were significantly attenuated when using the hERG pore mutants Y652A and F656A. Subacute effects of duloxetine on hERG channel expression were analyzed using the Western blot technique. We found that incubation with duloxetine results in a concentration-dependent decrease of channel surface expression. Whereas inhibitory effects of duloxetine seem negligible under therapeutically relevant concentrations, hERG block should be considered in cases of duloxetine overdose and when administering duloxetine to patients susceptible to drug-induced QT prolongation.
Choi,
Duloxetine blocks cloned Kv4.3 potassium channels.
2012,
Pubmed
Curran,
A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome.
1995,
Pubmed
Dennis,
hERG channel trafficking: novel targets in drug-induced long QT syndrome.
2007,
Pubmed
Derby,
The effects of supratherapeutic doses of duloxetine on blood pressure and pulse rate.
2007,
Pubmed
Ficker,
Mechanisms of arsenic-induced prolongation of cardiac repolarization.
2004,
Pubmed
Goldstein,
Duloxetine in the treatment of major depressive disorder.
2007,
Pubmed
Kiehn,
Pathways of HERG inactivation.
1999,
Pubmed
,
Xenbase
Kobayashi,
Inhibition of G protein-activated inwardly rectifying K+ channels by different classes of antidepressants.
2011,
Pubmed
,
Xenbase
Kuryshev,
Pentamidine-induced long QT syndrome and block of hERG trafficking.
2005,
Pubmed
Lantz,
Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects.
2003,
Pubmed
Mitcheson,
A structural basis for drug-induced long QT syndrome.
2000,
Pubmed
,
Xenbase
Priori,
Genetic defects of cardiac ion channels. The hidden substrate for torsades de pointes.
2002,
Pubmed
Rajamani,
Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.
2006,
Pubmed
Redfern,
Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
2003,
Pubmed
Roden,
Cardiac ion channels.
2002,
Pubmed
Sanguinetti,
HERG1 channelopathies.
2010,
Pubmed
Sanguinetti,
A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel.
1995,
Pubmed
,
Xenbase
Scherer,
Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents.
2009,
Pubmed
,
Xenbase
Scholz,
Inhibition of cardiac HERG channels by grapefruit flavonoid naringenin: implications for the influence of dietary compounds on cardiac repolarisation.
2005,
Pubmed
,
Xenbase
Scholz,
Biophysical properties of zebrafish ether-à-go-go related gene potassium channels.
2009,
Pubmed
,
Xenbase
Scholz,
Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired Long QT syndrome by antiparkinsonian drug budipine.
2003,
Pubmed
,
Xenbase
Scholz,
Anticholinergic antiparkinson drug orphenadrine inhibits HERG channels: block attenuation by mutations of the pore residues Y652 or F656.
2007,
Pubmed
,
Xenbase
Sharma,
Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor.
2000,
Pubmed
Thase,
Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine.
2005,
Pubmed
Vandenberg,
Temperature dependence of human ether-a-go-go-related gene K+ currents.
2006,
Pubmed
Wang,
Block of neuronal Na+ channels by antidepressant duloxetine in a state-dependent manner.
2010,
Pubmed
Wenzel-Seifert,
QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes.
2011,
Pubmed
Wong,
LY248686, a new inhibitor of serotonin and norepinephrine uptake.
1993,
Pubmed
Xue,
Treatment with duloxetine in adults and the incidence of cardiovascular events.
2012,
Pubmed
Zhang,
QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study.
2007,
Pubmed
